New treatment of ulcerative colitis with K-76
- 1 June 1992
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 35 (6), 560-567
- https://doi.org/10.1007/bf02050536
Abstract
The complement inhibitor K-76 (Otsuka Pharmaceutical Co., Osaka, Japan) was clinically evaluated as a new drug for treatment of active stage ulcerative colitis (UC). As monotherapy, K-76 proved effective in four of five cases. Furthermore, in patients with active stage UC that continued despite administration of corticosteroid hormone and salicylazosulphapyridine (so-called refractory UC), concomitant administration of K-76 was effective in seven of 21 cases. Thus, we believe that the multifunctional agent K-76 will provide clinicians with a new therapeutic approach to inflammatory bowel diseases, including UC and Crohn's disease.Keywords
This publication has 6 references indexed in Scilit:
- Epithelial Deposition of Immunoglobulin G1 and Activated Complement (C3b and Terminal Complement Complex) in Ulcerative ColitisGastroenterology, 1990
- Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum.Gut, 1989
- Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitisGastroenterology, 1986
- Effects of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on Various in vivo Immunological Reactions and on Experimental GlomerulonephritisComplement (Basel, Switzerland), 1984
- Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.Gut, 1980
- A Complement Inhibitor Produced by Stachybotrys complementi, nov. sp. K‐76, a New Species of Fungi ImperfectiMicrobiology and Immunology, 1980